The WHO and European Centre for Disease Prevention and Control found that antimicrobial resistance had worsened since 2019, leaving some patients with fewer effective treatment options.
Infections caused by drug-resistant Klebsiella pneumoniae, a common hospital bacterium, increased by an estimated 72% between 2019 and 2025.
The increase represents a substantial reversal of the target to reduce infections by 5%.
Cephalosporin-resistant E. coli infections rose by more than 16% instead of achieving the targeted 10% decline.
The WHO said key antibiotics failed against Klebsiella pneumoniae and Acinetobacter in at least half of tested samples in about one in two European countries. “The antibiotics doctors usually reach for first are failing against serious hospital infections,” WHO Europe Head of Health Security Dr Marc-Alain Widdowson said.
Doctors frequently turn to carbapenems when frontline antibiotics fail. The stronger medicines are normally reserved for severe infections. “When those stop working too, what’s left is mostly a small group of last-resort drugs that are often expensive and not available in every country,” Widdowson said.
“Each time one of these lines of defence falls, patients move closer to having no good options at all.”
Widdowson said patients were more likely to die in hospital when the first antibiotic prescribed failed against an infection.
The WHO said 16 of the 51 countries assessed lacked a standardised national approach and coordination system for responding to antimicrobial resistance.
Limited laboratory testing also meant doctors sometimes selected antibiotics without knowing which bacteria had caused an infection or whether the treatment would work.
The agency said inadequate data prevented health authorities from accurately tracking where resistance was spreading and assessing whether control measures were effective.
Stronger testing systems could allow patients to receive effective treatment sooner while giving authorities a clearer understanding of the threat, the WHO said.
The assessment recorded some progress involving drug-resistant Acinetobacter.
The estimated rate of bloodstream infections caused by the bacterium had almost halved from the elevated levels recorded during the COVID-19 pandemic in 2021.
Stronger surveillance, laboratory testing, national coordination and responsible antibiotic use were urgently needed to slow the spread of resistant infections, the WHO concluded.
–UN/ChannelAfrica–
